Takeda 4QFY22: Top Line Expands and Pipeline Development Progresses Despite OP Drop

Equity Bottom-Up

196 Views, 12 May 2022 19:08

EXECUTIVE SUMMARY

Takeda Pharmaceutical (4502 JP) reported 4QFY03/2022 results yesterday. Reported revenue grew 13.4% YoY to JPY873.3bn (vs consensus JPY825.7bn) while the company reported operating losses of JPY1.7bn.
Revenue from Top 14 drugs grew 20.3% YoY, while revenue from top-seller Entyvio grew 15.0% YoY during the quarter. Excluding Entyvio, other top 13 drugs grew 23.3% during the period.
Takeda’s shares moved down 2.0% at the end of yesterday’s trading and down 3% during today’s trade as profit drop disappointed the market.

detail (5-minute read)

WHAT’S TRENDING

Insights